REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

22/02/2019 17:35

RNS Number : 9275Q
GlaxoSmithKline PLC
22 February 2019
 


GlaxoSmithKline plc (the 'Company')
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr S Dingemans




b)


Position/status


Chief Financial Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB000




b)


Nature of the transaction


Acquisition of Ordinary Shares following the exercise of options granted on 29 October 2015 at the option price of £10.13 per Ordinary Share under the Company's ShareSave Plan. 




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£10.13


266




 
 
 




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 




e)


Date of the transaction


2019-02-22




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the exercise of options granted on 29 October 2015 at the option price of £10.13 per Ordinary Share under the Company's ShareSave Plan. 




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£10.13


888




 
 
 




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 




e)


Date of the transaction


2019-02-22




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mrs V Whyte




b)


Position/status


Company Secretary




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the exercise of options granted on 29 October 2015 at the option price of £10.13 per Ordinary Share under the Company's ShareSave Plan. 




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£10.13


888




 
 
 




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 




e)


Date of the transaction


2019-02-22




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDLLFLKLFLBBQ